Sales rose 13.2% to ¥2,037.1bn; core operating income jumped 60.9% to ¥202.8bn while net income fell 18.1% to ¥90.2bn. Full-year revenue and profit forecasts were raised.
Interim Phase III DASL-HiCaP results show darolutamide added to ADT and radiation significantly improves metastasis-free survival versus placebo in high‑risk patients.
Brings cosmetic actives and specialty ingredients to Australia and New Zealand, paired with local distribution, technical formulation support and Innovation & Application Centers.
New centrifuge adds about 30% capacity, improves plant reliability, and supports supply of Liquipac to New Zealand water‑treatment customers; separated solids are reused in soil‑aid products.
The 1 MW PEM electrolyzer will produce hydrogen for a refuelling station to supply dual‑fuel heavy trucks and help build South Island hydrogen infrastructure.
Strong cash flow and low leverage; all segments profitable. Chemicals lifted by Borouge International closing and higher olefin/polyolefin prices.
Net sales +5.2% organic H1; recurring EBIT margin 18.1%; closed Xella and Cementos Pacasmayo; FY2026 guidance raised to ~5% sales and ~10% recurring EBIT growth.
Sales rose 14% to ¥1,004.2bn; core operating income doubled to ¥114.1bn. Semiconductor demand, higher prices, FX and Middle East-driven naphtha effects boosted performance.
New coalition to strengthen domestic carbon markets: improve MRV, accounting, transparency and offsets. Open to nations with national compliance schemes; New Zealand and Germany have joined.
Q1: operating cash flow €776m (€1,624m excl NWC, +20%); net income €323m; leverage 17%. Energy down, Fuels flat, Chemicals up on Borealis reclass. and higher polyolefin margins; Borouge closed
